Bayer has received FDA approval for the CONTOUR NEXT LINK blood glucose meter to be paired with Medtronic‘s newly approved ‘artificial pancreas’, the MiniMed 530G with Enlite diabetes management system. Medtronic’s MiniMed 530G, which was approved in September, is the first FDA approved device to halt insulin delivery once measured glucose falls below a preset threshold. Bayer’s glucose meter is the first to be approved in the US and labeled for pairing with the MiniMed 530G.
The CONTOUR NEXT LINK glucometer links with the “artificial pancreas” to wirelessly communicate blood glucose levels to the Medtronic device. Based on the feedback from the CONTOUR NEXT LINK, when glucose is on a trend to be dangerously low, the MiniMed 530G warns the wearer about the potential condition. The wearer can then choose to pause delivery of insulin, but if the warning is ignored completely, the insulin flow is paused automatically to prevent hypoglycemia. The CONTOUR NEXT LINK uses a tiny blood sample size of 0.6μl and has a short countdown period of 5 seconds. Results are shown on a color display that can be read even in the dark. The Bayer device can also be connected to the computer for charging the battery and to download results into the Carelink therapy management software.
Press release: BAYER’S CONTOUR® NEXT LINK CLEARED FOR USE WITH MEDTRONIC’S NEW MiniMed® 530G with Enlite®
Product page: CONTOUR NEXT LINK…
Flashback: Medtronic’s Artificial Pancreas with Threshold Suspend Gets FDA Approval